181 results about "Acute renal failures" patented technology

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

Methods are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.

The present invention relates to methods of diagnosing, predicting and monitoring kidney diseases, including acute renal failure, renal tubular interstitial disease and glomerulonephritis. In particular, the present invention relates to the detection, prediction and monitoring of kidney diseases by detection of CXCR3 and CCL chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney diseases.

A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).

Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms / ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms / ml, with an infusion rate of 0.1-0.6 mg / kg IBW / hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg / kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms / ml (5-10 mg / l). The kidney is then transported to the recipient. The recipient is similarly preloaded with 5 mg / kg lean body mass aminophylline intravenously over 30-60 min with cardiac monitoring, with a constant infusion of 0.1-0.3 mg / kg lean body mass / hr continuing during the next 24 hours after the kidney is transplanted into the recipient.

Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.

The invention relates to a formula of a blood filtration replacement fluid which is special for citrate anticoagulation, a preparation method and a usage thereof. With the components of sodium citrate, sodium chloride, potassium chloride, sodium lactate, citric acid and so on, the replacement fluid is mainly used for blood filtration and blood dialysis filtration of the patients with acute renal failure or high risk bleeding due to multiple organ failure etc., and can solve the problems of easy occurrence of hypernatremia and alkali poisoning in the prior citrate anticoagulation, thus facilitating the clinical usage. The replacement fluid has the advantages of strong applicability, exact efficacy and low toxicity and side effects; the preparation process is simple; the quality is stable, safe and effective; the feasibility is strong; the repeatability is high; and the replacement fluid is applicable to the large-scale production and the promotion of the clinical application, thus being the ideal blood filtration replacement fluid for blood filtration, blood dialysis filtration, continuous renal replacement therapy and so on. The demand of the blood dialysis increases along with the increasing number of the patients with the end-stage renal failure year by year, so the blood filtration replacement fluid can generate more tremendous economic and social benefits.

Composition of matter for application to skin to administer fenoldopam by permeation through the skin, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The invention discloses injection of mannite and glycerol, which contains mannite, glycerol and water for injection. Furthermore, the invention also discloses a method for preparing the injection, which comprises the following steps: taking the mannite and the glycerol, dissolving into the water for injection, filtering and filling. The injection of the mannite and the glycerol is clinically used for treating cerebrovascular diseases, brain trauma, cerebral tumors, intracranial inflammation and the diseases of acute and chronic intracranial hypertension, hydrocephalus and the like caused by other reasons. The injection of the mannite and the glycerol has the functions of lowering the intracranial pressure quickly and eliminating the hydrocephalus and can also avoid death because of acute renal failure caused by the injury of the kidney; the injection of the mannite and the glycerol suppresses the apoptosis of neural cells and achieves the function of protecting the brain; the function of lowering the intracranial pressure is stable and has long retention time; crystals occurring because of the change of the air temperature or in the processes of storage and transportation are eliminated; and the glycerol is used as a caloric agent and can improve and recover the energy metabolism of the important viscera of the heart, the brain, the kidney and the like during oxygen deficiency. The injection of the mannite and the glycerol is a very effective, stable and safe medicine for promoting urination and removing water clinically.

The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.

The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).

The invention discloses a light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine, which is applied to haemodialysis ultra-filtration for treating diseases of acute renal failure, chronic renal failure, uremia, hypertension, arteriosclerosis, blood hyperviscosity, histanoxia and the like and belongs to the field of medical instruments. The LED phototherapy oxygenation type haemodialysis machine mainly comprises an LED phototherapy oxygenation part device, a blood extracorporeal circulation pipeline, a dialysate supply water pipeline and a circuit controlled by a microcomputer. The machine is characterized in that: the LED phototherapy oxygenation part device is embedded into an arterial cup clamper and a dialyser clamper of the blood extracorporeal circulation pipeline by a plurality of small-sized LED multi-wavelength penetration nails. In the process of haemodialysis, part of or all of lamps in the LED phototherapy oxygenation device can operate according to a specific situation for carrying out on-line irritation on blood in the circulation pipeline by utilizing a principle of strong penetrating power of LED multi-wavelength, so that blood circulation can be improved, agglutination of erythrocytes, platelet aggregation and blood viscosity are reduced, the flow rate of blood is improved, antithrombin is activated, the content of thrombin is reduced, coagulation and hemostasis mechanisms are adjusted, and the aim of treatment is achieved.

Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.

A method preserving renal medullary blood flow in a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE analog to the human or non-human animal in an amount sufficient to attenuate a fall in renal medullary blood flow following a renal disorder. In addition, a method for preventing and treating ischemic acute renal failure is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat ischemic acute renal failure.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

This invention belongs to the field of biotechnology detection, particularly relates to a triple kit for early warning, treatment process and monitoring after treatment of renal failure, and further discloses a preparation method and application thereof. Serum cystatin (CysC), neutrophil gelatinase-associated lipocalin (NAGL) and C reactive protein (CRP) are used as detecting markers. The triple kit uses NGAL-CysC-CRP triple antibody as the markers, can effectively monitor the risk of renal failure, especially plays an unexpected effect of monitoring of acute renal failure of persons subjected to a traffic accident, and is high in diagnosis sensitivity of acute renal failure, and strong in specificity, the clinical monitoring accuracy is as high as 95%, and the triple kit can make nephropathy self testing and monitoring of persons with diabetes possible, is used for kidney disease early warning, can timely prevent deterioration of the patient's condition, and reduces the patient's degree of kidney damage.

The invention relates to the fields of organic synthesis and medicinal chemistry and in particular relates to an O-(piperidyl)ethyl derivative of cleistanone, a preparation method and application of the O-(piperidyl)ethyl derivative to preparation of medicines for resisting acute renal failure (ARF). The invention synthesizes a new O-(piperidyl)ethyl derivative of cleistanone and discloses the preparation method of the O-(piperidyl)ethyl derivative. Pharmacology experiments show that the O-(piperidyl)ethyl derivative of cleistanone has the function of resisting ARF and has the value of developing the medicines for resisting ARF.

The invention discloses a traditional Chinese preparation for treating acute renal failure. The traditional Chinese preparation is prepared by selecting bulk drugs respectively in parts by weight as follows: 20-30 g of rhubarb, 10-20 g of cassia twig, 10-20 g of poria cocos, 10-20 g of rhizoma alismatis,10-20 g of rhizoma imperatae, 10-20 g of buffalo horn, 10-20 g of Cirsium japonicum, 10-20 g of safflower, 10-20 g of figwort roots, 8-15 g of tetrapanax papyriferus, 8-12 g of peach kernel, 8-12 g of antelope horn powder, 8-12 g of white mulberry root-bark, 8-12 g of semen lepidii, 8-12 g of polygonum aviculare and 8-12 g of dianthus superbus. All the drugs are compatible to achieve tonification and purgation in combination, and together play the function of reinforcing Qi and nourishing blood, activating blood circulation to dissipate blood stasis, clearing heat and detoxifying, achieving cathartic purpose, and alleviating water retention and freeing strangury. The traditional Chinese preparation is obvious in curative effect, free of negative or side effects and high in cure rate when used for treating acute renal failure, requires a short time for recovering renal function normality, achieves low probability of recurrence after curing and is worthy of clinical popularization and application.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention relates to a method for determining the presence of renal damage in an individual and also to a method for detecting one or several proteins selected from the list comprising Reg3B, fetuin B, Ras-related GTP-binding protein A serine protease inhibitor A3L, subunit 1 of COP9, gamma subunit of ATP synthase, gelsolin, ribonuclease UK114, aminoacylase 1A, alpha-enolase, keratin 5, parvalbumin alpha, ribonuclease 4 or serine protease inhibitor A3K. The renal damage may be acute renal failure. Said renal pathologies may be caused by the administration of a nephrotoxic agent, wherein the nephrotoxic agent may be an aminoglycoside antibiotic such as gentamicin, or cisplatin. The invention also provides means to differentiate the renal damage or renal failure induced by gentamicin from that induced by cisplatin, through the biochemical analysis of the urinary level of Reg3B and / or gelsolin, or fragments thereof.

The invention relates to the use of a group of Chinese medicinal compositions in treating acute kidney failure and / or enhancing immunity, wherein the medicinal composition comprises the following raw materials (by weight portion): rhizome of Sichuan lovage 15-200 weight parts, astragalus root 40-450 weight parts, Chinese angelica root 20-220 weight parts, epimedium 15-185 weight parts, dried rehmannia root 15-205 weight parts, alisol 15-185 weight parts and poria cocos wolf 15-185 weight parts.